
Organovo Holdings ONVO
Quarterly report 2025-Q4
added 02-11-2026
Organovo Holdings EV - Enterprise Value 2011-2026 | ONVO
Annual EV - Enterprise Value Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.05 M | 594 K | -1.78 M | -16.7 M | 28.9 M | 83.2 M | 94.5 M | 228 M | 195 M | 316 M | 381 M | 5.43 B | 191 M | -329 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.43 B | -16.7 M | 494 M |
EV - Enterprise Value of other stocks in the Diagnostics research industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-19.1 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
92.6 M | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
45.8 B | $ 117.74 | -1.68 % | $ 35.8 B | ||
|
Burning Rock Biotech Limited
BNR
|
433 M | $ 19.95 | -2.97 % | $ 211 M | ||
|
Check-Cap Ltd.
CHEK
|
2.55 M | - | - | $ 9.42 M | ||
|
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
15 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
39.2 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
70.4 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
1.04 B | $ 22.11 | 25.81 % | $ 1.18 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
26.2 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.64 B | - | -17.87 % | $ 25.9 M | ||
|
Exact Sciences Corporation
EXAS
|
22 B | - | - | $ 19.8 B | ||
|
Enzo Biochem
ENZ
|
-22.7 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
-1.92 M | $ 1.42 | - | $ 1.89 M | ||
|
Castle Biosciences
CSTL
|
665 M | $ 24.49 | -0.53 % | $ 680 M | ||
|
Global Cord Blood Corporation
CO
|
-2.77 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
6.64 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
9.21 B | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
251 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
11.4 B | $ 179.73 | -0.51 % | $ 8.91 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
5.02 B | - | - | $ 10.7 B | ||
|
Danaher Corporation
DHR
|
145 B | $ 194.65 | -1.74 % | $ 139 B | ||
|
Interpace Biosciences
IDXG
|
16.3 M | $ 1.93 | -12.09 % | $ 8.54 M | ||
|
Heska Corporation
HSKA
|
851 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
3.16 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
15.3 B | $ 130.0 | -1.71 % | $ 20.7 B | ||
|
Medpace Holdings
MEDP
|
14 B | $ 521.19 | 0.51 % | $ 15 B | ||
|
Fulgent Genetics
FLGT
|
502 M | $ 16.04 | -0.8 % | $ 485 M | ||
|
NeoGenomics
NEO
|
1.85 B | $ 8.39 | -3.34 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
2.26 B | $ 9.18 | -2.55 % | $ 1.99 B | ||
|
Guardant Health
GH
|
15.2 B | $ 85.27 | 0.48 % | $ 10.7 B | ||
|
QIAGEN N.V.
QGEN
|
11.3 B | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
990 K | $ 2.84 | -3.07 % | $ 92.2 K | ||
|
Biomerica
BMRA
|
6.63 M | $ 2.19 | 4.03 % | $ 5.03 M | ||
|
Koninklijke Philips N.V.
PHG
|
13.2 B | $ 29.07 | - | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
26.4 B | $ 115.89 | -0.52 % | $ 9.56 B | ||
|
Laboratory Corporation of America Holdings
LH
|
33.1 B | $ 267.91 | 0.38 % | $ 22.3 B | ||
|
Motus GI Holdings
MOTS
|
568 K | - | -34.28 % | $ 263 K | ||
|
Celcuity
CELC
|
5.57 B | $ 122.94 | -0.43 % | $ 5.75 B | ||
|
Senseonics Holdings
SENS
|
376 M | $ 6.78 | -1.74 % | $ 283 M | ||
|
Myriad Genetics
MYGN
|
598 M | $ 5.16 | -0.67 % | $ 478 M | ||
|
Lantheus Holdings
LNTH
|
5.9 B | $ 83.51 | -0.51 % | $ 5.64 B | ||
|
Soleno Therapeutics
SLNO
|
2.13 B | $ 52.62 | 0.1 % | $ 2.67 B | ||
|
Neuronetics
STIM
|
168 M | $ 1.36 | -2.52 % | $ 89.7 M | ||
|
Quest Diagnostics Incorporated
DGX
|
22.9 B | $ 193.55 | 1.16 % | $ 21.5 B | ||
|
ENDRA Life Sciences
NDRA
|
4.49 M | $ 5.2 | 1.17 % | $ 4.09 M | ||
|
Thermo Fisher Scientific
TMO
|
186 B | $ 522.74 | -1.65 % | $ 197 B | ||
|
Invitae Corporation
NVTA
|
2.11 B | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
432 M | $ 17.81 | -0.17 % | $ 399 M |